Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?

about

Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?

Item

http://www.wikidata.org/entity/Q47250471

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Diabetic macular edema, innova ...... ardy Region healthcare system?

@en

Diabetic macular edema, innova ...... ardy Region healthcare system?

@nl

type

Item

label

Diabetic macular edema, innova ...... ardy Region healthcare system?

@en

Diabetic macular edema, innova ...... ardy Region healthcare system?

@nl

prefLabel

Diabetic macular edema, innova ...... ardy Region healthcare system?

@en

Diabetic macular edema, innova ...... ardy Region healthcare system?

@nl

P1476

Diabetic macular edema, innova ...... ardy Region healthcare system?

@en

P2093

Andrea Fomiatti

http://www.w3.org/2001/XMLSchema#string

Camilla Ferri

http://www.w3.org/2001/XMLSchema#string

Davide Croce

http://www.w3.org/2001/XMLSchema#string

Emanuela Foglia

http://www.w3.org/2001/XMLSchema#string

Gianpiera Gambaro

http://www.w3.org/2001/XMLSchema#string

Giovanni Staurenghi

http://www.w3.org/2001/XMLSchema#string

Innocente Figini

http://www.w3.org/2001/XMLSchema#string

Massimo Medaglia

http://www.w3.org/2001/XMLSchema#string

Michela Franzin

http://www.w3.org/2001/XMLSchema#string

Patrizia Tadini

http://www.w3.org/2001/XMLSchema#string

P2860

Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema.

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.

Prevalence of diabetic retinopathy in the United States, 2005-2008.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Intravitreal aflibercept for diabetic macular edema.

Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.

Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System

P304

e468-e474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AOS.13620

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Bandello

Lucrezia Ferrario

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29240298

http://www.w3.org/2001/XMLSchema#string